Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2025)

Top pharmaceutical stocks in 2025 ranked by overall Due Diligence Score. See the best pharmaceutical stocks to buy now, according to analyst forecasts for the drug manufacturers - specialty & generic industry.

According to Due Diligence Score, the 3 best pharma stocks to buy right now are:

Neurocrine Biosciences (NASDAQ:NBIX) is the top pharmaceutical stock with a Due Diligence Score of 75, which is 50 points higher than the pharmaceutical industry average of 25. It passed 25 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 4.48% over the past year, overperforming other pharmaceutical stocks by 38 percentage points.

Neurocrine Biosciences has an average 1 year price target of $165.93, an upside of 15.83% from Neurocrine Biosciences's current stock price of $143.26.

Neurocrine Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Neurocrine Biosciences, 46.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amphastar Pharmaceuticals (NASDAQ:AMPH) is the second best pharmaceutical stock with a Due Diligence Score of 60, which is 35 points higher than the pharmaceutical industry average of 25. It passed 20 out of 33 due diligence checks and has strong fundamentals. Amphastar Pharmaceuticals has seen its stock lose -36.41% over the past year, underperforming other pharmaceutical stocks by -3 percentage points.

Amphastar Pharmaceuticals has an average 1 year price target of $60.50, an upside of 69.47% from Amphastar Pharmaceuticals's current stock price of $35.70.

Amphastar Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Amphastar Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Siga Technologies (NASDAQ:SIGA) is the third best pharmaceutical stock with a Due Diligence Score of 57, which is 32 points higher than the pharmaceutical industry average of 25. It passed 21 out of 38 due diligence checks and has strong fundamentals. Siga Technologies has seen its stock return 19.25% over the past year, overperforming other pharmaceutical stocks by 53 percentage points.

Out of 6 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 9.64%, which is 7 percentage points higher than the pharmaceutical industry average of 2.98%.

Siga Technologies's dividend payout ratio of 50% indicates that its high dividend yield is sustainable for the long-term.

Perrigo Co (NYSE:PRGO) has an annual dividend yield of 3.47%, which is the same as the pharmaceutical industry average of 2.98%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -95.3% indicates that its dividend yield might not be sustainable for the long-term.

Phibro Animal Health (NASDAQ:PAHC) has an annual dividend yield of 2.31%, which is -1 percentage points lower than the pharmaceutical industry average of 2.98%. Phibro Animal Health's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Phibro Animal Health's dividend has shown consistent growth over the last 10 years.

Phibro Animal Health's dividend payout ratio of 111.6% indicates that its dividend yield might not be sustainable for the long-term.

Pharmaceutical stocks were up 0.02% in the last day, and up 3.28% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are up.

Based on WallStreetZen's Valuation Score, the 3 most undervalued pharmaceutical stocks right now are:

Collegium Pharmaceutical (NASDAQ:COLL) is the most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Collegium Pharmaceutical has a valuation score of 71, which is 58 points higher than the pharmaceutical industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 1.86% in the past year. It has overperformed other stocks in the pharmaceutical industry by 35 percentage points.

Amphastar Pharmaceuticals (NASDAQ:AMPH) is the second most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Amphastar Pharmaceuticals has a valuation score of 71, which is 58 points higher than the pharmaceutical industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Amphastar Pharmaceuticals's stock has dropped -36.41% in the past year. It has underperformed other stocks in the pharmaceutical industry by -3 percentage points.

Biofrontera (NASDAQ:BFRI) is the third most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Biofrontera has a valuation score of 43, which is 30 points higher than the pharmaceutical industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Biofrontera's stock has dropped -42.41% in the past year. It has underperformed other stocks in the pharmaceutical industry by -9 percentage points.